Reformulation Clause Samples

Reformulation. Dyax shall remain responsible for any activities relating to the reformulation of the Product, including those that are conducted in connection with the EMA approved Pediatric Investigational Plan.

Reformulation. As of the Effective Date, Daiso shall not distribute, sell or offer for sale Products in California unless (a) the Products contain no more than 1,000 parts per million (0.1%) of DEHP or DBP (“Reformulated Products”), or (b) the Products are distributed, sold, or offered for sale with a clear and reasonable warning as described below in Section 2.2.

Reformulation. The Covered Product shall be deemed to comply with Proposition 65 and be exempt from any Proposition 65 warning requirements with respect to lead if the Covered Product contains no more than

Reformulation. We reformulate the collision avoidance constraints as

Reformulation. As of the Effective Date, Harbor Freight shall not manufacture or distribute the Products for sale in California unless (a) the Products contain no more than 1,000 parts per million (0.1%) of DEHP, DBP, or DINP, and no more than 100 parts per million (0.01%) of Lead (“Reformulated Product”), or (b) the Product is distributed, sold, or offered for sale with a clear and reasonable warning as described below in Section 2.2. The only Products excluded from this requirement are those that have already been distributed to California retailers as of October 31, 2020

Reformulation. As of ninety (90) days after the Effective Date, ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ shall not sell or caused to have the Products sold in California unless (a) the Products contain no more than 100 parts per million (0.01%) of Lead (“Reformulated Product”), or (b) the Product is distributed, sold, or offered for sale with a clear and reasonable warning as described below in Section 2.2. The requirements set forth in this Section 2 shall not apply to any Products that as of the Effective Date are in the stream of commerce or are otherwise in ▇▇▇▇▇ ▇▇▇▇▇▇▇▇’▇ inventory stock as of such Effective Date.

Reformulation. As of the Effective Date, Zoetop shall not distribute, sell or offer for sale the Products in California unless (a) the Products contain no more than 1,000 parts per million (0.1%) of DEHP or DBP, and no more than 200 parts per million of Lead (“Reformulated Product”), or (b) the Product is distributed, sold, or offered for sale with a clear and reasonable warning as described below in Section 2.2.

Reformulation. In addition to the obligation to warn under Section 2.3, Invacare represents it has begun reviewing the option to reformulate under Section 2.2 to meet a concentration limit of 1000 parts per million (0.1%) for DEHP in all accessible components of the Products manufactured, imported or sold in California on and after the Compliance Date subject to commercial feasibility. For purposes of this Section 2.2, commercial feasibility refers to the following material factors: (1) the availability of other materials that do not incorporate other substances regulated under Proposition 65 (“New Materials”); (2) performance characteristics, including efficacy, durability, and stability, of any New Materials or the resulting product; (3) the availability and reliability of the supply of New Materials; and (4) whether there are any material cost considerations for the use of New Materials. If Invacare’s reasonable efforts lead to the commercial feasibility to meet the reformulation standard referenced in Section 2.2.2 for a subset of Products, Invacare may elect to reformulate such products.

Reformulation. As of the Effective Date, Travel Plus shall not distribute, sell or offer for sale the Products in California unless (a) the Products contain no more than 1,000 parts per million (0.1%) of DEHP (“Reformulated Product”), or (b) the Products is distributed, sold, or offered for sale with a clear and reasonable warning as described below in Section 2.2.